Role of eIF6 in Modulating Response to BRAF Inhibitors and Acquired Resistance in Cutaneous Melanoma

Role of eIF6 in Modulating Response to BRAF Inhibitors and Acquired Resistance in Cutaneous Melanoma

Saved in:

Bibliographic Details
Main Authors:	G. Kyriakopoulos, A. Petropoulou, A. Bania, V.S. Stamatakis, A. Alexiou, A. Anastogianni, S. Georgiou, C. Stathopoulos, K. Grafanaki
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001241
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma
by: Josué Ballesteros-Álvarez, et al.
Published: (2024-10-01)

Predicting BRAF Mutations in Cutaneous Melanoma Patients Using Neural Network Analysis
by: Oleksandr Dudin, et al.
Published: (2024-01-01)

SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells
by: Melissa Bernhardt, et al.
Published: (2025-01-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

Braf-Mutant Melanomas: Biology and Therapy
by: Elvira Pelosi, et al.
Published: (2024-12-01)

Cutaneous adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis
by: Junhui Qian, et al.
Published: (2024-12-01)

Exceptional response to rechallenge of BRAF/MEK inhibitors in patients with primary acquired resistance to targeted therapy
by: B. Ziółkowska, et al.
Published: (2024-01-01)

Global trends and emerging insights in BRAF and MEK inhibitor resistance in melanoma: a bibliometric analysis
by: Jianhao Bai, et al.
Published: (2025-01-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
by: Yu. S. Shakh-Paronyants, et al.
Published: (2023-03-01)

Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma
by: Ian F Hermans, et al.
Published: (2024-04-01)

Circulating tumor DNA: a promising biomarker in stage III BRAF+ melanoma
by: G. Roccuzzo, et al.
Published: (2024-01-01)

Melanoma genomics – will we go beyond BRAF in clinics?
by: Justyna Mirek, et al.
Published: (2024-09-01)

Macrophages: A Key Population for the Resistance Acquisition in BRAF Mutant Melanoma
by: P. Sisó Camarasa, et al.
Published: (2024-01-01)

Patient treatment preferences in unresectable/metastatic BRAF-mutated melanoma: a qualitative study
by: T. Amaral, et al.
Published: (2024-01-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
by: Eva Marie Erfurth, et al.
Published: (2024-12-01)

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
by: Victoria Jennings, et al.
Published: (2022-03-01)

Fulminant Disseminated Intravascular Coagulation as Initial Presentation of BRAF-Mutated Melanoma
by: Jeremy Chuang, et al.
Published: (2019-01-01)

Novel Prognostic Markers for Skin Cutaneous Melanoma
by: Zhang Y, et al.
Published: (2024-11-01)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
by: Yasar Subutay Peker, et al.
Published: (2018-01-01)

Mandibular metastasis of cutaneous melanoma
by: Josi Amadeu, et al.
Published: (2016-09-01)

Clinical Characteristics of Cutaneous Melanoma and Second Primary Malignancies in a Dutch Hospital-Based Cohort of Cutaneous Melanoma Patients
by: Haike M. J. van der Velden, et al.
Published: (2009-01-01)

Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells
by: Ceyda Colakoglu Bergel, et al.
Published: (2025-01-01)

Girolline is a sequence context-selective modulator of eIF5A activity
by: Tilman Schneider-Poetsch, et al.
Published: (2025-01-01)

Occupationally Acquired American Cutaneous Leishmaniasis
by: Maria Edileuza Felinto de Brito, et al.
Published: (2012-01-01)

The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanoma
by: L. Mortier, et al.
Published: (2024-01-01)

Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma
by: Brenen P. Swofford, et al.
Published: (2017-01-01)

The Olive Oil Monophenolic Secoiridoid Ligstroside Aglycone Suppresses Melanoma Progression by Targeting the BRAF Signaling Pathway
by: Md Ashiq Mahmud, et al.
Published: (2025-01-01)

Genetics of Uveal Melanoma and Cutaneous Melanoma: Two of a Kind?
by: Thomas van den Bosch, et al.
Published: (2010-01-01)

Use of Immune Checkpoint Inhibitor (ICI) Therapy for Cutaneous Melanoma from 2014 to 2021 in Norway: Insights from Real-World Data
by: D. Reis Costa, et al.
Published: (2024-01-01)

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
by: Dirk Schadendorf, et al.
Published: (2022-12-01)

Locally acquired cutaneous larva migrans in Ontario?
by: Manreet Dhaliwal, et al.
Published: (2024-11-01)

Melanoma Metabolism: Molecular Mechanisms and Therapeutic Implications in Cutaneous Oncology
by: Isabella J. Tan, et al.
Published: (2024-11-01)

Utilization of EGFR, ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany
by: Nikolaj Rischke, et al.
Published: (2024-12-01)

Pharmacokinetic Evaluation of [C]CEP-32496 in Nude Mice Bearing BRAF Mutation-Induced Melanomas
by: Cuiping Jiang MMSc, et al.
Published: (2018-09-01)

Sonography of the Primary Cutaneous Melanoma: A Review
by: Ximena Wortsman
Published: (2012-01-01)

Lessons from Cancer Immunoediting in Cutaneous Melanoma
by: Mariana Aris, et al.
Published: (2012-01-01)

Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma
by: Corina Daniela Ene, et al.
Published: (2020-01-01)

Worldwide Increasing Incidences of Cutaneous Malignant Melanoma
by: Dianne E. Godar
Published: (2011-01-01)

Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma
by: Angela Sandru, et al.
Published: (2014-01-01)

Assessment of performance in clinical risk prediction tools for cutaneous melanoma in the UK population
by: R. Manton, et al.
Published: (2024-01-01)